Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 11/24/21 → 10/26/22 |
Funding
- Regeneron Pharmaceuticals Incorporated: $35,136.00
Covid-19 Clinical Research: A Phase 1B, Open-Label, Singel Dose Study Assessing the Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous, Anti-Spike(s) SARS-COV-2 Monoclonal Antibodies Casirivimab+Imdevimab for the Treatment
- Nachman, Sharon (PI)
- Beneri, Christy (CoPI)
- Handel, Andrew (CoPI)
Project: Research